Oral On-demand KVD900 Rapidly Reduces HAE Attack Severity

Oral On-demand KVD900 Rapidly Reduces HAE Attack Severity

297624

Oral On-demand KVD900 Rapidly Reduces HAE Attack Severity

KVD900, an oral experimental on-demand treatment for swelling episodes caused by hereditary angioedema (HAE), safely and significantly reduced the severity of attacks and shorted the time to improvement, which was maintained for 24 hours, according to Phase 2 trial data.  “Our goal is to provide the best outcome for HAE patients experiencing an attack, and that means offering them the ability to treat early in the attack progression to shorten attack duration,” Andrew Crockett, CEO…

You must be logged in to read/download the full post.